DailyIQ
Last updatedjust now

BNTX·BioNTech SE

$88.73
-0.28 (-0.31%)
After Hours
High
$90.50
Open
$89.01
Market Cap
24.08B
52W High
$124.00
Low
$88.57
P. Close
$88.73
P/E
-
52W Low
$79.52
Fwd P/E
-16.12
DailyIQ Est.
$122.10
Inst. Ownership
6.2%
Short Interest
0.93%
Days to Cover
3.1
Technical Score (1D)
33
BEARISH
News Sentiment
35
BEARISH
On Oct 13, BioNTech announced that its AHEAD‑MERIT Phase 2/3 trial of the mRNA cancer candidate BNT113 combined with pembrolizumab failed to meet the primary progression‑free survival endpoint in advanced HPV‑linked head and neck cancer. The miss highlighted the scientific challenges of applying mRNA technology to solid tumors and raised doubts about the candidate’s ability to extend patient survival. BioNTech said the trial would continue to evaluate overall survival as a secondary outcome, indicating the program is not abandoned but faces increased uncertainty. The setback was reported to dampen investor enthusiasm for the company’s oncology pipeline and could delay the revenue timeline associated with the program. The company’s shares fell after the announcement, reflecting the market’s reaction to the missed milestone.
LOW TARGET
$76 -14.8%
2 analysts
MEAN TARGET
$116 +30.6%
15 analysts
HIGH TARGET
$143 +61.5%
12 analysts
PRICE RANGE
$75.56 - $143.17
SB / B / H / S / SS
6/15/6/1/1
DAILYIQ EST.
$122.10 (+37.7%)
Sector
Healthcare
Industry
Biotechnology
Exchange
NMS
Country
Germany
Symbol
BNTX
Description
BioNTech SE is a German biotechnology firm specializing in the development and commercialization of immunotherapies for cancer and infectious diseases. The company's core value proposition lies in its pipeline of innovative drug candidates, currently undergoing clinical trials. These trials span various phases and target a range of solid tumors, including advanced melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer. BioNTech's diverse portfolio also includes therapies in development for other cancers, such as urothelial carcinoma and small cell lung cancer. Established in 2008, BioNTech is headquartered in Mainz, Germany, and is focused on advancing its innovative approach to cancer treatment.
Bought (1Y)
0 shares
$0
Sold (1Y)
858,209 shares
$84.2M
Sahin UgurChief Executive Officer
Sell36,209 shares2026-10-09
Sahin UgurChief Executive Officer
Sell27,000 shares2026-10-08
Sahin UgurChief Executive Officer
Sell24,000 shares2026-10-07
Sahin UgurChief Executive Officer
Sell21,000 shares2026-10-06
Sahin UgurChief Executive Officer
Sell72,000 shares2026-10-05
95/ 100
Strong bullish
Overall: Bullish
✓Analyst target above current price
Earnings Summary
BioNTech SE is a German biotechnology company focused on developing immunotherapies for cancer and infectious diseases, with a pipeline that includes mRNA and protein‑based candidates targeting solid tumors such as melanoma, head and neck squamous cell carcinoma, and non‑small cell lung cancer. The company operates in the highly competitive healthcare biotechnology sector, where clinical success and regulatory approvals drive valuation. In the most recent quarter, Q4 2025, BioNTech reported an EPS of –$0.33 versus an estimate of –$2.02, a significant improvement in profitability, while revenue rose to $907 million against an estimate of $321 million, reflecting a strong upside in top‑line performance. Compared to Q4 2024, where EPS was $1.08 and revenue $1.19 billion, the company experienced a sharp decline in earnings but maintained robust revenue growth, indicating a shift toward cost containment and higher sales volumes. Historically, BioNTech has shown a mixed earnings trajectory: while revenue has grown year‑over‑year, EPS has fluctuated between positive and negative territory, with the company beating revenue estimates in three of the last four quarters but missing EPS estimates in two. This pattern suggests that while sales are expanding, profitability remains volatile, likely due to ongoing R&D expenditures. Recent news highlights a setback in the AHEAD‑MERIT Phase 2/3 trial of BNT113, which failed to meet its primary progression‑free survival endpoint in advanced HPV‑linked head and neck cancer; this development has dampened investor enthusiasm and could delay the revenue timeline for that program. Key will be how BioNTech balances its pipeline development costs against the incremental revenue from its existing product portfolio in the coming quarter.

EPS

EstBeatMiss
$-2.80$-1.70$-0.61$0.49$1.59Q4'24Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.86 - -
Q2'26$-2.13$-2.24-5.1%
Q1'26$-2.29$-1.95+15.0%
Q4'25$-2.02$-0.33+83.9%
Q4'24$0.37$1.08+188.9%

Revenue

EstBeatMiss
$-56M$296M$648M$1.0B$1.4BQ4'24Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.1B - -
Q2'26$161M$107M-33.7%
Q1'26$249M$118M-52.5%
Q4'25$321M$907M+182.8%
Q4'24 - $1.2B -

Market Data

BNTX Stock Snapshot

BEARISH33/100
$88.66−$0.07 (0.1%)
Market cap
24.08B
Day range
$88.57 – $90.50
News sentiment
35/100 · Bearish
Analyst target
$115.77 (+30.6%)
Consensus
Buy · 29 analysts
52-week range+11.5% off low · -28.5% from high
$79.52$124.00
Price $88.66 DailyIQ Est. $122.10

The signals on BNTX lean bearish, and the range position backs that up. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Behaviour On Record

What BNTX's own history says about today's numbers

Realized volatility (21d)
44.1% 36th pct
Below its peak
-79.7%
vs 200-day average
-8.2%
Up days (1y)
49%

BioNTech SE is currently running 44.1% annualised volatility over the last 21 sessions. Measured against BNTX's own 7 years of daily returns rather than a market-wide average, that is the 36th percentile — on the quiet side for this stock, against a typical reading of 52.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BNTX is trading -79.7% below its running peak. Across 6 full years on file, its median worst-drawdown-in-a-year was -43.1%, and the deepest was -50.1% in 2021. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -8.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 39th percentile — close to the gap it normally carries. Over the past year BNTX closed higher on 49% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 8 years of records, BNTX finished the month higher 5 of 8 times, with a median return of +1.2% and an average of +3.0%. Its strongest month historically has been November at +19.1% on average, its weakest February at -4.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BNTX has opened more than 2% away from the prior close in 243 of 1,758 sessions (13.8% of the time), with the largest gaps running +55.7% and -10.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, BNTX moved an average of 2.5% in the session after earnings, closing higher 3 of those 3 times, with a median move of +0.9% and a largest of +6.6%.

All figures computed from 1,760 daily closes between 2019-10-10 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against BNTX's own 7-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BNTX's sector?

BioNTech SE sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, BNTX ranks 9th of 15 tracked industries, improving.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82
Industry rank
#9 of 15

Options Market

What is the options market pricing for BNTX?

CallsPuts

For BioNTech SE's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.61), with at-the-money implied volatility around 53.4%. The options market is pricing roughly a ±4.7% move by that expiry — a range of about $91.32–$100.36.

Put/call ratio (2026-10-16)
0.61
ATM implied volatility
53.4%
Total open interest
12,429
Expected move by 2026-10-16
±4.7% ($91.32–$100.36)

Analyst Rating Changes

Are analysts turning bullish or bearish on BNTX?

Canaccord Genuity most recently reiterated its rating on BioNTech SE to Buy on Oct 14, 2026 with a price target of $132 (from $136). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
Canaccord Genuity — Buy
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Oct 14, 2026Canaccord GenuityMaintainedBuy$136 → $132
Oct 7, 2026Morgan StanleyMaintainedOverweight$115 → $114
Sep 8, 2026BMO CapitalDowngradeOutperform → Market Perform$128 → $105
Aug 31, 2026Canaccord GenuityMaintainedBuy$142 → $136
Aug 5, 2026CitigroupMaintainedBuy$130 → $125
Aug 5, 2026Evercore ISI GroupMaintainedOutperform$135 → $130
Jul 8, 2026Morgan StanleyMaintainedOverweight$126 → $119
May 27, 2026UBSUpgradeNeutral → Buy$117 → $135
May 22, 2026BernsteinInitiatedMarket Perform$96
May 6, 2026Canaccord GenuityMaintainedBuy$171 → $158
May 6, 2026Wells FargoMaintainedOverweight$150 → $140
Apr 27, 2026HC Wainwright & Co.ReiteratedBuy$130

Peers

BNTX peers

News Sentiment Analysis

Sentiment gathered from recent headlines

35/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
In October 2026 BioNTech reported that its AHEAD‑MERIT Phase 2/3 trial of the mRNA cancer candidate BNT113 combined with pembrolizumab failed to meet the primary progression‑free survival endpoint in advanced HPV‑linked head and neck cancer. The setback underscores the scientific challenges of applying mRNA technology to solid tumors and raises doubts about the candidate’s ability to extend patient survival. The company will continue to evaluate overall survival data, but the miss is likely to dampen investor enthusiasm for its oncology pipeline.
What did this article say?
BioNTech (BNTX) announced that its Phase 2/3 trial of the mRNA oncology drug BNT113 in head and neck cancer failed to meet the progression‑free survival primary endpoint. The company decided to continue the study to evaluate overall survival as a secondary outcome. The result signals a setback for BNTX’s oncology pipeline, though the company maintains optimism about the drug’s potential.
What did this article say?
BioNTech’s oncology program suffered a setback when its Phase 3 trial failed to meet the primary efficacy endpoint, prompting a decline in the company’s shares. The trial, which evaluated the company’s novel immunotherapy in a large patient cohort, did not demonstrate the expected improvement in overall survival. The loss of a key milestone is expected to delay the company’s revenue timeline and may impact investor confidence.
What did this article say?
BioNTech’s stock closed at $96.96, prompting investors to evaluate whether the price reflects the company’s oncology and infectious disease pipeline. The firm’s recent trading has been volatile, with a modest three‑month rebound but long‑term shareholders still experiencing significant losses. Analysts estimate a fair value around $118 per share, suggesting the current price may be undervalued relative to future pipeline prospects. No new contracts or guidance changes were announced, leaving the market to interpret existing data.
What did this article say?
BioNTech’s share price fell 60.3% over five years as the company shifts focus from its COVID‑19 vaccine peak to its oncology pipeline and manufacturing restructuring. Planned closures of German and Singapore sites and the transfer of vaccine production to Pfizer were highlighted as potential cost‑saving measures that could alter future capacity and revenue projections. Analysts debated whether the current $95.73 price reflects the company’s ongoing sales base or a discounted valuation based on pandemic‑era earnings. The uncertainty surrounding future sales prospects and restructuring outcomes weighed on investor sentiment, contributing to a negative outlook for the stock.
What did this article say?
Morgan Stanley analyst Terence Flynn reduced BioNTech’s price target from $115 to $114 while keeping an Overweight stance. The downgrade reflects a modest reassessment of the company’s near‑term valuation. The change signals a slight negative view on the firm’s upside potential, though the overall recommendation remains positive.
What did this article say?
The article contrasts Moderna and BioNTech (BNTX) as leaders in mRNA technology, noting both companies’ expansion beyond COVID-19 vaccines into cancer therapies and seasonal influenza. It outlines Moderna’s recent RSV and flu vaccine launches and its EU‑approved flu/COVID combination, while highlighting BioNTech’s broader platform ambitions. The piece evaluates each firm’s fundamentals and growth prospects, ultimately presenting a balanced view without a definitive recommendation. No material corporate action or earnings update is discussed, leaving the investment outlook unchanged.
What did this article say?
In September 2026, BioNTech (BNTX) secured Health Canada approval for its Omicron XFG‑adapted COMIRNATY vaccine, expanding its COVID‑19 portfolio. Earlier, the company announced that its investigational CTLA‑4 antibody, gotistobart, nearly doubled median overall survival in a Phase 3 lung cancer trial, providing a strong oncology signal. These developments reinforce BNTX’s strategy to diversify beyond vaccines and support a more sustainable revenue model.
What did this article say?
BioNTech’s share price remains depressed despite recent Phase 3 data showing its lung‑cancer therapy, gotistobart, nearly doubled median overall survival versus chemotherapy. The company’s long‑term valuation is under scrutiny, with analysts debating whether current pricing reflects a solid revenue base or speculative expectations. The 71.5% decline over five years fuels concerns that the stock may still be overvalued relative to its sales profile.
What did this article say?
BioNTech's Phase 3 trial of its lung cancer therapy gotistobart showed a nearly two‑fold increase in median overall survival versus standard chemotherapy, providing a robust clinical signal. The data lifted BNTX shares modestly, with a 3.9% rise in the last 30 days and 4.9% over 90 days, while the stock remains trading at roughly a 22% discount to analyst targets. The result strengthens the company’s oncology portfolio and may improve valuation expectations, but long‑term upside remains uncertain as the firm continues to operate at a loss.

Technical Analysis

Real-time indicators across multiple timeframes

33
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $1.54B combined position · 14 adding, 9 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
FMR LLC (Fidelity)▲ Buy7,571,8052.82%$704.56M2026-08-13
BlackRock, Inc.▲ Buy1,854,9660.69%$172.60M2026-08-07
Temasek Holdings (Private) Ltd• Hold1,506,0270.56%$140.14M2026-08-07
Baillie Gifford & Co▼ Sell592,3800.22%$55.12M2026-08-06
Goldman Sachs Group Inc▲ Buy589,9030.22%$54.89M2026-08-14
Morgan Stanley▲ Buy492,0920.18%$45.79M2026-08-13
Bank of America Corp▼ Sell486,2050.18%$45.24M2026-08-14
Balyasny Asset Management L.P.▲ Buy463,1630.17%$43.10M2026-08-14
D. E. Shaw & Co., Inc.▲ Buy417,4210.16%$38.84M2026-08-14
Marshall Wace, LLP▲ Buy382,1470.14%$35.61M2026-08-13
Citadel Advisors LLC▼ Sell364,5850.14%$33.92M2026-09-02
Citigroup Inc▲ Buy359,7840.13%$33.48M2026-08-03
Point72 Asset Management, L.P.▼ Sell327,1840.12%$30.44M2026-08-14
Two Sigma Investments, LP▲ Buy292,6140.11%$27.23M2026-08-14
Squarepoint Ops LLC▲ Buy199,0040.07%$18.52M2026-08-14
Geode Capital Management, LLC▲ Buy142,8520.05%$13.29M2026-08-12
Wellington Management Group LLP▼ Sell130,3340.05%$12.13M2026-08-14
JPMorgan Chase & Co▲ Buy126,9750.05%$11.97M2026-08-12
Susquehanna International Group, LLP▼ Sell126,6160.05%$11.78M2026-08-14
Invesco Ltd.▲ Buy100,4620.04%$9.35M2026-08-14
Palo Alto Investors LP• Hold19,6140.01%$1.83M2026-08-19
Wells Fargo & Company▲ Buy17,9730.01%$1.67M2026-08-14
Verition Fund Management LLC▼ Sell4,6580.00%$433.4K2026-08-14
Northern Trust Corp▼ Sold out00.00%$02026-08-13
Millennium Management LLC▼ Sold out00.00%$02026-08-14
Q2 2026 flow:3.60M sh bought ($335.06M)1.45M sh sold ($134.91M)net +2.15M sh (+$200.15M)
Congressional Trading Activity
1 disclosed trades · ~$8.0K est. traded value · 0 buys, 1 sells
MemberChamberStateTypeAmountTradedFiled
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-08-072025-09-12